Neutra Corp. (NTRR) Fair Value 2026

NTRR · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.1 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-08-27, Neutra Corp. (NTRR) trades at $0.00. QOC: 5.1/10. Value Trap Risk: 26/100 (LOW). 0/13 models active.

Key Facts

Ticker
NTRR
Price
$0.00
Quality Score
5.1/10
Value Trap Risk
26/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give NTRR?

0 Intrinsic Value Models vs. Current Price ($0.00)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Neutra Corp. (NTRR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Neutra Corp. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About NTRR?

0 of 13 models are currently active for NTRR. See which stocks rank higher →

How Does NTRR Rank in Drug Manufacturers - Specialty & Generic?

Among 110 Drug Manufacturers - Specialty & Generic stocks, NTRR ranks #76 by Quality of Company score. CirclFi's QOC score of 5.1/10 evaluates 32 fundamental signals. A score of 5.1 reflects mixed fundamentals.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

The Drug Manufacturers - Specialty & Generic sector introduces analytical considerations specific to biopharma enterprise businesses. For Neutra Corp., metrics like R&D productivity ratio provide important context that general-purpose valuation models may underweight.

Is NTRR a Value Trap?

CirclFi's Value Trap algorithm assigns NTRR a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Neutra Corp.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Neutra Corp. scores 5.1 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every NTRR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Neutra Corp. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

AMLXAmylyx Pharmaceuticals, Inc.QOC 5.1IXHLIncannex Healthcare Inc.QOC 5.1IMCCIM Cannabis Corp.QOC 5.2CANNTrees CorporationQOC 5.1SKYISky Century Investment, Inc.QOC 5.2APUSApimeds Pharmaceuticals US, Inc.QOC 5.0CTTHCTT Pharmaceutical Holdings, Inc.QOC 3.3HIMSHims & Hers Health, Inc.QOC 7.9EVOEvotec SEQOC 6.2UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: AMLX · IXHL · IMCC · CANN · SKYI · APUS · CTTH · HIMS · EVO · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to NTRR?

7 companies across all industries closest to NTRR’s Quality of Company score of 5.1/10.

MEHAFunctional Brands Inc.QOC 5.1IGCIGC Pharma, Inc.QOC 5.1PBTPermian Basin Royalty TrustQOC 5.1ROYLRoyale Energy, Inc.QOC 5.1GPUSHyperscale Data, Inc.QOC 5.1DMACDiaMedica Therapeutics Inc.QOC 5.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: MEHA · IGC · PBT · ROYL · GPUS · DMAC · NVDA

Where Does NTRR Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

NTRR is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Neutra Corp.’s Valuation?

What is Neutra Corp.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Neutra Corp. (NTRR). The Quality of Company score is 5.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is NTRR overvalued or undervalued right now?

At $0.00, 0 of 0 active models suggest NTRR may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Neutra Corp.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 5.1 mean for NTRR?

Neutra Corp.'s QOC of 5.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on NTRR?

CirclFi analyzes NTRR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is NTRR a value trap in 2026?

Neutra Corp.'s Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Neutra Corp. (NTRR) a Quality of Company score of 5.1/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/NTRR/ · Methodology
Primary sources for this NTRR valuation
  • Financial statements: Neutra Corp. 10-K and 10-Q filings on SEC EDGAR (CIK 0001512886) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for NTRR as of ; valuations recomputed .